Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
3 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.

DFN-15 may be effective in relieving migraine

Elaine Soliven
14 Jul 2020

Treatment with DFN-15 may effectively alleviate pain and the most bothersome symptoms in adults with episodic migraine, according to two phase III studies presented at AHS 2020.

“DFN-15, a 120 mg oral celecoxib solution has demonstrated rapid absorption in healthy subjects, … [but] the efficacy of celecoxib, a selective COX-2 inhibitor, for episodic migraine has not been established,” according to study investigator Dr Sagar Munjal from Dr. Reddy’s Laboratories Incorporated in Princeton, New Jersey, US.

The researchers conducted two identical, multicentre, double-blind, phase III studies involving adults with episodic migraine (2–8 per month) to assess the efficacy and safety of DFN-15 in  these patients. Participants were randomized to receive either DFN-15 or placebo (study 1; n=631) and were then rerandomized in a second double-blind study period (study 2; n=622). Of these, only 80.5 percent (study 1) and 80.1 percent (study 2) completed the study treatment. [AHS 2020]

A significantly higher percentage of individuals on DFN-15 were pain free at 2 hours post-dosing than those on placebo in study 1 (32.8 percent vs 23.5 percent; p=0.02) and study 2 (35.6 percent vs 21.7 percent; p<0.001).

More subjects in the DFN-15 arm vs the placebo arm also experienced freedom from the most bothersome symptom (eg, nausea, photophobia, and phonophobia) at 2 hours post-dosing in both studies (58.1 percent vs 43.9 percent; p=0.003 in study 1 and 57.8 percent vs 44.8 percent; p=0.007 in study 2).

Similarly, more DFN-15-treated subjects experienced pain relief (moderate, severe to mild, or no pain at 2 hours) compared with placebo-treated patients in study 1 (67.9 percent vs 55.3 percent; p=0.004) and study 2 (74.5 percent vs 60.5 percent; p<0.001).

The rates of treatment-emergent adverse events (TEAEs) were comparable between the DFN-15 and the placebo groups (below 14 percent), with no serious TEAEs or deaths reported.

The researchers also found no remarkable findings in ECGs, vital signs, laboratory tests, or in any other safety endpoints.

“[Overall,] in [the] two phase III placebo-controlled studies, … DFN-15 may be an effective alternative to oral triptans … [and was found to be] effective for the acute treatment of migraine,” Munjal concluded.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
3 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.